JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

HKG:2126 Revenue

JW (Cayman) Therapeutics Co. had revenue of 111.35M CNY in the half year ending June 30, 2026, with 28.26% growth. This brings the company's revenue in the last twelve months to 288.66M, up 62.40% year-over-year. In the year 2025, JW (Cayman) Therapeutics Co. had annual revenue of 283.65M with 79.28% growth.

• Revenue (ttm): 288.66M CNY
• Revenue Growth: +62.40%
• P/S Ratio: 2.68
• Revenue / Employee: 952.67K CNY
• Employees: 303
• Market Cap: 892.97M HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	283.65M	125.44M	79.28%
Dec 31, 2024	158.22M	-15.64M	-8.99%
Dec 31, 2023	173.86M	28.15M	19.32%
Dec 31, 2022	145.70M	114.91M	373.10%
Dec 31, 2021	30.80M	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 17, 2026

Data Sources Report a data error